ACDIMA subsidiary the Egyptian International Pharma. Industries Company (EIPICO) is planning to set up a biosimilar production facility at a cost of up to EGP 1 bn, Al Mal reports. EIPICO is expecting to soon finalize procedures to acquire a 10k sqm land plot in 10th of Ramadan for the facility. Biosimilars have recently been approved to help in chemotherapy cancer treatments, and can also be used to treat hormone-related disorders.

Tags: